ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2019 American Transplant Congress

    Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma

    M. Nazzal1, R. Steele2, R. Ray3, N. Phillips2, J. Long4, R. Ray2

    1Surgery, Saint Louis University, Saint Louis, MO, 2Pathology, Saint Louis University, Saint Louis, MO, 3Internal Medicine, Saint Louis University, Saint Louis, MO, 4Comparative Medicine, Saint Louis University, Saint Louis, MO

    *Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…
  • 2019 American Transplant Congress

    Long Term Impact of Intraoperative Autologous Blood Transfusion on HCC Recurrence in Liver Transplantation

    G. Kelly1, J. L. Pasko1, E. Dewey2, E. Maynard1, S. L. Orloff1, C. Enestvedt1

    1Division of Abdominal Transplant, OHSU, Portland, OR, 2Department of General Surgery, OHSU, Portland, OR

    *Purpose: The aim of this study was to determine whether intraoperative autologous transfusion in liver transplant patients with HCC affects the rate of recurrence.*Methods: We…
  • 2019 American Transplant Congress

    DOME: A New Strategy for Prioritizing Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist

    C. Rickert1, M. Akan2, Z. Leung3, J. F. Markmann1, S. Tayur2, H. Zhao3, H. Yeh1

    1Massachusetts General Hospital, Boston, MA, 2Tepper School of Business, Carnegie Mellon University, Pittsburgh, PA, 3City University of Hong Kong, Hong Kong, China

    *Purpose: Currently, adult HCC patients are prioritized for liver transplantation by receiving MELD exception points, determined primarily by time on waitlist without regard to actual…
  • 2019 American Transplant Congress

    Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis

    A. Thorat, L. Jeng, S. Hsu, H. Yang, C. Yeh, T. Chen, K. Poon, P. Li

    Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan

    *Purpose: The elderly patients > 65 years with end-stage liver disease that require liver transplantation has been steadily increased over last decade in Taiwan and…
  • 2019 American Transplant Congress

    Adjuvant Immunotherapeutic Approach For Liver Transplant Recipients With Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

    M. Ohira1, R. Hotta1, Y. Imaoka1, K. Sato1, Y. Tanaka1, A. G. Tzakis2, S. Nishida3, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2Cleveland Clinic Florida, Weston, FL, 3New York Medical College, Valhalla, NY

    *Purpose: Although liver transplantation (LT) is a preferred treatment for selected patients with Hepatocellular carcinoma (HCC), HCC-recurrence would be a still important medical problem. Most…
  • 2019 American Transplant Congress

    Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation

    D. Kim, J. Lee, S. Kim, K. In, D. Joo, S. Kim, M. Kim

    Severance hospital, Seoul, Korea, Republic of

    *Purpose: There was no distinct guideline how to take into account the effect of pretransplant locoregional treatment (LRT) in hepatocellular carcinoma (HCC) staging system. The…
  • 2019 American Transplant Congress

    Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation

    N. Mehta1, J. Guy2, C. Frenette3, P. Tabrizian4, M. Hoteit5, R. Dhanasekaran6, J. Dodge1, M. L. Holzner4, L. Frankul3, S. Florman4, N. Parikh7, F. Yao1

    1UCSF, San Francisco, CA, 2CPMC, San Francisco, CA, 3Scripps Hospital, La Jolla, CA, 4Mt Sinai, New York, NY, 5U. Pennsylvania, Philadelphia, PA, 6Stanford, Palo Alto, CA, 7U. Michigan, Ann Arbor, MI

    *Purpose: Recent studies from United Network of Organ Sharing (UNOS) Region 5 reported excellent outcomes after liver transplantation (LT) after successful down-staging in HCC patients…
  • 2019 American Transplant Congress

    Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome

    S. Radunz1, A. Kirschner1, J. M. Theysohn2, C. Schotten3, T. Benkö1

    1General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, 2Diagnostic and Interventional Radiology and Neurradiology, University Hospital Essen, Essen, Germany, 3Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany

    *Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…
  • 2019 American Transplant Congress

    Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcioma

    M. Najjar1, K. Bruestle1, P. Jiang1, S. Robbins-Juarez1, R. Hwang1, A. Mathur1, E. C. Verna1, A. Griesemer1, B. Samstein1, T. Kato1, Y. M. Saenger1, K. J. Halazun2, J. C. Emond1

    1Columbia University Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY

    *Purpose: Mixed hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis than…
  • 2019 American Transplant Congress

    Resource Utilization in Hepatocellular Carcinoma Liver Transplantation before and after the Six Month Wait Time

    J. Sokolich1, W. McClellan2, J. Buggs1, E. Rogers1, K. Barber1, K. Cocuy1, A. Kumar2

    1Tampa General Hospital, Tampa, FL, 2University of South Florida, Tampa, FL

    *Purpose: The purpose of this study was to determine any difference in resource utilization since the implementation of the mandatory six month wait-time policy for…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences